Nomura Asset Management Co. Ltd. Has $11.45 Million Stock Position in Insulet Corporation $PODD

Nomura Asset Management Co. Ltd. cut its stake in Insulet Corporation (NASDAQ:PODD) by 75.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,449 shares of the medical instruments supplier’s stock after selling 113,022 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Insulet were worth $11,452,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Larson Financial Group LLC grew its position in Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 81 shares during the period. IFP Advisors Inc lifted its holdings in shares of Insulet by 823.4% during the first quarter. IFP Advisors Inc now owns 1,265 shares of the medical instruments supplier’s stock valued at $332,000 after acquiring an additional 1,128 shares during the period. Wealth Alliance LLC boosted its stake in shares of Insulet by 8.6% in the 1st quarter. Wealth Alliance LLC now owns 1,037 shares of the medical instruments supplier’s stock valued at $272,000 after purchasing an additional 82 shares in the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Insulet by 22.0% in the 1st quarter. Allianz Asset Management GmbH now owns 139,016 shares of the medical instruments supplier’s stock worth $36,507,000 after purchasing an additional 25,095 shares during the last quarter. Finally, GW&K Investment Management LLC increased its position in shares of Insulet by 114.7% during the 1st quarter. GW&K Investment Management LLC now owns 249 shares of the medical instruments supplier’s stock worth $65,000 after purchasing an additional 133 shares in the last quarter.

Insulet Stock Up 3.9%

Shares of PODD opened at $346.36 on Thursday. The business’s fifty day moving average price is $322.93 and its two-hundred day moving average price is $314.19. The firm has a market capitalization of $24.37 billion, a price-to-earnings ratio of 105.28, a PEG ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s quarterly revenue was up 29.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity

In related news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.39% of the company’s stock.

Analysts Set New Price Targets

PODD has been the subject of several analyst reports. Piper Sandler lifted their price target on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Wolfe Research raised their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Truist Financial boosted their target price on Insulet from $365.00 to $390.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Morgan Stanley restated an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Oppenheimer raised their price target on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $376.35.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.